-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Rongchang Bio released its prospectus, and the company's revenue growth in 2021 is particularly impressive, with a year-on-year increase of 468 times
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
Revenue increased 468 times, 5 new category 1 drugs on the way
On March 14, Rongchang Bio disclosed a letter of intent for listing on the Science and Technology Innovation Board, and officially entered the issuance stage.
The number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
The number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
In November 2020, Rongchang Bio was listed on the Hong Kong Stock Exchange.
If the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
If the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
In 2021, Rongchang Bio's annual revenue will reach 1.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
According to the prospectus, from 2018 to 2020, the compound annual growth rate of R&D expenses of Rongchang Bio was 46.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
Rongchang Bio listed drugs
Source: MED2.
0 China Drug Evaluation Data from Minet
0 China Drug Evaluation Data from Minet
Category 1 new drug Taitacept (RC18) and Category 2.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
Judging from the candidate drugs under research, RC-28 has entered the clinical phase II, and the four RC88, RC98, RC108 and RC118 are all in the clinical phase
I.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
I.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
Rongchang Bio's clinical stage drugs
Source: Minet China Drug Clinical Trials Publicity Library
Sprinting into the field of ADC and dual-antibody drugs, the market is expected to exceed $40 billion
In terms of process technology, Rongchang Biotechnology focuses on the research and development of therapeutic antibody drugs such as antibody conjugated drugs (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
In recent years, ADC drugs and bispecific antibodies have become hotspots in the development of new drugs
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
The global development history of ADC drugs has been more than 20 years, and it has experienced four generations of development
.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
According to the global new drug research and development data of Minet.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
Globally approved ADC drugs
Source: Minet Global New Drug Research and Development Database
In terms of the research and development progress of domestic ADC drugs, related drugs from companies such as Bio-Tech and TOT have entered the clinical phase III, and companies such as Hengrui, Kelun, and Meyake are in the clinical phase II
.
.
From the perspective of bispecific antibody drugs, due to the technical difficulty of research and development, there are very few bispecific antibody drugs on the market at present
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
Double Antibody Drugs Listed Worldwide
Source: Minet Global New Drug Research and Development Database
According to the global new drug research and development data of Minet.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
Source: Mi Intranet database, company announcements, etc.
Recently, Rongchang Bio released its prospectus, and the company's revenue growth in 2021 is particularly impressive, with a year-on-year increase of 468 times
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
Revenue increased 468 times, 5 new category 1 drugs on the way
On March 14, Rongchang Bio disclosed a letter of intent for listing on the Science and Technology Innovation Board, and officially entered the issuance stage.
The number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
The number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
In November 2020, Rongchang Bio was listed on the Hong Kong Stock Exchange.
If the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
If the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
In 2021, Rongchang Bio's annual revenue will reach 1.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
According to the prospectus, from 2018 to 2020, the compound annual growth rate of R&D expenses of Rongchang Bio was 46.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
Rongchang Bio listed drugs
Source: MED2.
0 China Drug Evaluation Data from Minet
0 China Drug Evaluation Data from Minet
Category 1 new drug Taitacept (RC18) and Category 2.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
Judging from the candidate drugs under research, RC-28 has entered the clinical phase II, and the four RC88, RC98, RC108 and RC118 are all in the clinical phase
I.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
I.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
Rongchang Bio's clinical stage drugs
Source: Minet China Drug Clinical Trials Publicity Library
Sprinting into the field of ADC and dual-antibody drugs, the market is expected to exceed $40 billion
In terms of process technology, Rongchang Biotechnology focuses on the research and development of therapeutic antibody drugs such as antibody conjugated drugs (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
In recent years, ADC drugs and bispecific antibodies have become hotspots in the development of new drugs
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
The global development history of ADC drugs has been more than 20 years, and it has experienced four generations of development
.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
According to the global new drug research and development data of Minet.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
Globally approved ADC drugs
Source: Minet Global New Drug Research and Development Database
In terms of the research and development progress of domestic ADC drugs, related drugs from companies such as Bio-Tech and TOT have entered the clinical phase III, and companies such as Hengrui, Kelun, and Meyake are in the clinical phase II
.
.
From the perspective of bispecific antibody drugs, due to the technical difficulty of research and development, there are very few bispecific antibody drugs on the market at present
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
Double Antibody Drugs Listed Worldwide
Source: Minet Global New Drug Research and Development Database
According to the global new drug research and development data of Minet.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
Source: Mi Intranet database, company announcements, etc.
Recently, Rongchang Bio released its prospectus, and the company's revenue growth in 2021 is particularly impressive, with a year-on-year increase of 468 times
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
.
At present, Rongchang Bio has developed more than 20 candidate innovative drug projects, of which tacitabine and vedicitumab have been approved for marketing, and have achieved "insurance in the same year as they were launched".
In addition, 5 new class 1 drugs have been approved Entering the clinical trial stage, focusing on the field of ADC drugs
.
Revenue increased 468 times, 5 new category 1 drugs on the way
Revenue increased 468 times, 5 new category 1 drugs on the way On March 14, Rongchang Bio disclosed a letter of intent for listing on the Science and Technology Innovation Board, and officially entered the issuance stage.
The number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
disease disease diseaseThe number of shares in the initial public offering of Rongchang Bio is about 54.
4263 million shares, and it plans to raise 4 billion yuan, which will be used for new biological drug industrialization projects.
, Anti-tumor antibody new drug research and development projects, autoimmune and ophthalmic disease antibody new drug research and development projects,
etc.
In November 2020, Rongchang Bio was listed on the Hong Kong Stock Exchange.
If the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
standard standard standardIf the company is successfully listed on the Science and Technology Innovation Board, the company will become an "H+A" pharmaceutical stock
.
For this A-share listing, Rongchang Biotech adopted the fifth set of listing standards on the Science and Technology Innovation Board.
Rongchang Biotech specifically stated that if the company cannot guarantee profitability in the next few years (that is, the audited net profit before and after deducting non-recurring gains and losses ( (including retroactively restated) is negative and operating income (including retroactively restated) is less than 100 million yuan, or the audited net assets (including retroactively restated) are negative), the company may face delisting after listing of A shares risk
.
In 2021, Rongchang Bio's annual revenue will reach 1.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
43 billion yuan, a year-on-year increase of 46753.
31%, and its net profit will be 280 million yuan, a year-on-year increase of 139.
59%
.
Judging from the current revenue situation, Rongchang Bio is expected to be stable in the A-share market of the Science and Technology Innovation Board in the future
.
According to the prospectus, from 2018 to 2020, the compound annual growth rate of R&D expenses of Rongchang Bio was 46.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
7%, and the total R&D expenses exceeded 1 billion yuan
.
In 2021, the company's research and development expenses will reach 710 million yuan, a year-on-year increase of 52.
63%
.
Rongchang Biological adheres to the development model of first-in-class and best-in-class.
At present, it has developed more than 20 candidate innovative biological products, of which 2 have been approved for marketing, 5 This product has entered the clinical trial stage (excluding new drugs that have been marketed to develop new indications)
.
Among these 7 drugs, 6 are Class 1 new drugs
.
Rongchang Bio listed drugs
Source: MED2.
0 China Drug Evaluation Data from Minet
0 China Drug Evaluation Data from Minet
Category 1 new drug Taitacept (RC18) and Category 2.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
2 improved new drug Vidicitumumab (RC48) have both achieved “insurance in the same year as they were launched”.
Yuan / branch (specification 60mg)
.
Taitacept was approved for the treatment of systemic lupus erythematosus in March 2021, and the revenue in the first half of 2021 was 29.
1919 million yuan; Veldicitumab was approved in June 2021, making it the first domestically marketed ADC At present, the drug has been approved for two indications of metastatic gastric cancer and urothelial cancer
.
As of the end of 2021, the sales force of Vidicitumumab is about 180, and the sales amount in 2022 is expected to be about 400 million yuan
.
Judging from the candidate drugs under research, RC-28 has entered the clinical phase II, and the four RC88, RC98, RC108 and RC118 are all in the clinical phase
I.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
medicines medicines medicinesI.
Among them, RC88, RC108, and RC118 are ADC drugs, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world
.
In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
.
Rongchang Bio's clinical stage drugs
Source: Minet China Drug Clinical Trials Publicity Library
Sprinting into the field of ADC and dual-antibody drugs, the market is expected to exceed $40 billion
Sprinting into the field of ADC and dual-antibody drugs, the market is expected to exceed $40 billion In terms of process technology, Rongchang Biotechnology focuses on the research and development of therapeutic antibody drugs such as antibody conjugated drugs (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
.
Among them, ADC drugs and bispecific antibodies are the current focus areas of the company, including 7 ADC drugs and 5 bispecific antibody drugs
.
In recent years, ADC drugs and bispecific antibodies have become hotspots in the development of new drugs
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
.
According to industry estimates, the global drug market in both fields is expected to exceed $40 billion in the next few years
.
The global development history of ADC drugs has been more than 20 years, and it has experienced four generations of development
.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
medicine medicine medicine.
In 2000, Pfizer's gemtuzumab was approved for marketing, becoming the world's first approved ADC drug
.
However, ADC drugs did not cause a lot of waves in the global pharmaceutical industry at that time, and at that time, the drug had high off-target toxicity and low drug efficacy, so it was withdrawn from the market in 2010, and then reintroduced in 2017 with a lower graded dose.
listed
.
In 2018, the global ADC drug research and development boom broke out.
Compared with the first-generation gemtuzumab, the latest generation of ADC drugs represented by goxatuzumab achieved high DAR value, low toxicity and strong stability and other improvements.
, one of its features is the use of camptothecin-like TOP1 inhibitors as toxins with low toxicity
.
According to the global new drug research and development data of Minet.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
com, there are currently more than 600 new ADC drug projects under research in the world, but most of them are in the drug discovery and preclinical stages.
Vebtuzumab, Goxatuzumab, Tilimumab, Velbutuximab, etc.
Among them, Roche's trastuzumab, emmet, will have global sales of CHF 1.
982 billion in 2021
.
Globally approved ADC drugs
Source: Minet Global New Drug Research and Development Database
In terms of the research and development progress of domestic ADC drugs, related drugs from companies such as Bio-Tech and TOT have entered the clinical phase III, and companies such as Hengrui, Kelun, and Meyake are in the clinical phase II
.
enterprise enterprise enterprise.
From the perspective of bispecific antibody drugs, due to the technical difficulty of research and development, there are very few bispecific antibody drugs on the market at present
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
.
In 2009, TRION's catuximab was approved for marketing, the world's first bispecific antibody drug
.
However, among the first bispecific antibody drugs on the market for more than ten years, only three new bispecific antibody drugs have been launched in the world: Roche's Emicizumab, Johnson & Johnson's Evantuzumab, and Amgen's Bilintuzumab
.
In 2020, the global sales of Roche's emeclizumab reached 2.
19 billion Swiss francs, becoming the first bispecific antibody drug to enter the global TOP100 in sales at that time.
In 2021, the sales of this drug have exceeded 3 billion Swiss francs
.
Double Antibody Drugs Listed Worldwide
Source: Minet Global New Drug Research and Development Database
According to the global new drug research and development data of Minet.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
com, there are more than 1,000 bispecific antibody drug research projects in the world.
In addition to 4 listed drugs, 3 have submitted marketing applications, including cadonilimab (NMPA) of Kangfang Bio, Roche Faricimab from Boehringer Ingelheim and ozolizumab from Boehringer Ingelheim, in addition, 12 drugs from companies such as Corning Jereh, Baili Tian, Pfizer, Novo Nordisk and other companies have entered the phase III clinical stage
.
From this point of view, the cadonilimab of Kangfang Bio is expected to become the first domestic double-antibody drug in the future
.
Source: Mi Intranet database, company announcements, etc.
Source: Mi Intranet database, company announcements, etc. 
